Plain-English translation of NCT06105151 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called VV119 that may help treat schizophrenia. Researchers want to understand how safe the medication is, how well people tolerate it, and how the body absorbs and processes it. This is the first time the medication is being tested in humans.
Before a medication can be prescribed to patients, it must first be tested in healthy volunteers to make sure it is safe and to understand how the body handles it. This trial is an important first step in developing this new treatment.
You likely qualify if…
You likely don't qualify if…
Participants will receive a single dose of the medication (or placebo) and have their safety and blood levels monitored. Part of the study tests how eating a large, fatty meal affects how the body processes the medication. The trial involves physical exams, blood tests, and heart monitoring at a single research center.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Vigonvita Life Sciences
Enrollment target
~82 participants
Started
October 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huaqing Duan
Beijing Anding Hospital of Capital Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.